These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 182463)

  • 1. 16Beta-hydroxydehydroepiandrosterone: the dichotomy between renal receptor binding and urinary electrolyte activity.
    Funder JW; Robinson JA; Feldman D; Wynne KN; Adam WR
    Endocrinology; 1976 Aug; 99(2):619-28. PubMed ID: 182463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of 16beta-hydroxydehydroepiandrosterone with renal mineralocorticoid receptors.
    Higgins JR; Wambach G; Kem DC; Gomez-Sanchez C; Holland OB; Kaplan NM
    J Lab Clin Med; 1977 Feb; 89(2):250-6. PubMed ID: 137938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineralocorticoid activity of 16beta-hydroxydehydroepiandrosterone and related steroids.
    Gomez-Sanchez C; Holland OB; Higgins JR; Mathieu R; Gruber GM; Milewich L; Kaplan NM
    J Lab Clin Med; 1976 Oct; 88(4):571-7. PubMed ID: 135037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for a new mineralocorticoid in patients with low-renin essential hypertension.
    Sennett JA; Brown RD; Island DP; Yarbro LR; Watson JT; Slaton PE; Hollifield JW; Liddle GW
    Circ Res; 1975 Jun; 36(6 Suppl 1):2-9. PubMed ID: 124232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineralocorticoid receptors in human kidney.
    Matulich DT; Spindler BJ; Schambelan M; Baxter JD
    J Clin Endocrinol Metab; 1976 Nov; 43(5):1170-4. PubMed ID: 993320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal receptor-binding activity of reduced metabolites of aldosterone: evidence for a mineralocorticoid effect outside of the classic aldosterone receptor system.
    Gomez-Sanchez CE; Smith JS; Ferris MW; Gomez-Sanchez EP
    Endocrinology; 1984 Aug; 115(2):712-5. PubMed ID: 6086276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineralocorticoid and renal receptor binding activity of 21-deoxyaldosterone.
    Koshida H; Miyamori I; Soma R; Matsubara T; Ikeda M; Takeda R; Nakamura S; Kiuchi F; Tsuda Y
    Endocrinology; 1990 Mar; 126(3):1410-5. PubMed ID: 2155101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RU-26988--a new tool for the study of the mineralocorticoid receptor.
    Gomez-Sanchez CE; Gomez-Sanchez EP
    Endocrinology; 1983 Sep; 113(3):1004-9. PubMed ID: 6307658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of glycyrrhetinic acid to kidney mineralocorticoid and glucocorticoid receptors.
    Ulmann A; Menard J; Corvol P
    Endocrinology; 1975 Jul; 97(1):46-51. PubMed ID: 166832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of rat brain aldosterone receptors reveals high affinity for corticosterone.
    Beaumont K; Fanestil DD
    Endocrinology; 1983 Dec; 113(6):2043-51. PubMed ID: 6227474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone receptors and the evaluation of plasma mineralocorticoid activity in normal and hypertensive states.
    Baxter JD; Schambelan M; Matulich DT; Spindler BJ; Taylor AA; Bartter FC
    J Clin Invest; 1976 Sep; 58(3):579-89. PubMed ID: 182723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 19-Nor deoxycorticosterone (19-nor DOC): mineralocorticoid receptor affinity higher than aldosterone, electrolyte activity lower.
    Funder JW; Mercer J; Ingram B; Feldman D; Wynne K; Adam WR
    Endocrinology; 1978 Oct; 103(4):1514-7. PubMed ID: 744165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Equivalent affinity of aldosterone and corticosterone for type I receptors in kidney and hippocampus: direct binding studies.
    Sheppard KE; Funder JW
    J Steroid Biochem; 1987 Dec; 28(6):737-42. PubMed ID: 2826920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of steroids in hypertension: evaluation of plasma mineralocorticoid activity with aldosterone receptors.
    Baxter JD; Schambelan M; Matulich DT; Spindler BJ; Bartter FC
    Clin Sci Mol Med Suppl; 1976 Dec; 3():321s-324s. PubMed ID: 1071637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Affinity of 18,19-dihydroxydeoxycorticosterone and 18-hydroxy-19-nor-deoxycorticosterone to aldosterone receptor and their mineralocorticoid activity.
    Okamoto M; Momoi K; Yamano T; Nakamura M; Odaguchi K; Shimizu T; Okada T; Terasawa T
    Biochem Int; 1983 Dec; 7(6):687-94. PubMed ID: 6237653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mineralocorticoid specificity of renal type I receptors: binding and metabolism of corticosterone.
    Doyle D; Smith R; Krozowski ZS; Funder JW
    J Steroid Biochem; 1989 Aug; 33(2):165-70. PubMed ID: 2549303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrinsic mineralocorticoid agonist activity of some nonsteroidal anti-inflammatory drugs. A postulated mechanism for sodium retention.
    Feldman D; Couropmitree C
    J Clin Invest; 1976 Jan; 57(1):1-7. PubMed ID: 173739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies.
    Funder J; Myles K
    Endocrinology; 1996 Dec; 137(12):5264-8. PubMed ID: 8940344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineralocorticoid specificity of renal type I receptors: in vivo binding studies.
    Sheppard K; Funder JW
    Am J Physiol; 1987 Feb; 252(2 Pt 1):E224-9. PubMed ID: 3030124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor binding and biological activity of 18-oxocortisol.
    Gomez-Sanchez CE; Gomez-Sanchez EP; Smith JS; Ferris MW; Foecking MF
    Endocrinology; 1985 Jan; 116(1):6-10. PubMed ID: 2856875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.